CRVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corvus Pharmaceuticals Inc (CRVS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. While the company has promising analyst ratings and potential catalysts in its pipeline, the recent financial performance is weak, and technical indicators suggest a bearish trend. Additionally, there are no significant trading signals or news catalysts to support immediate action.
The MACD is negative and expanding (-0.438), indicating bearish momentum. RSI is at 24.909, which is near oversold levels but not a clear buy signal. Moving averages are converging, showing no strong trend. The stock is trading below the pivot level (17.398) and close to the first support level (16.317), suggesting limited upside in the short term.
Analysts have significantly raised price targets, citing strong Phase 1 data for soquelitinib in atopic dermatitis. The drug shows potential to be first-in-class with expansion opportunities into other indications. Analysts view the recent weakness as a buying opportunity.
The stock has experienced a sharp regular market decline (-9.98%) and a pre-market drop (-3.20%). Financials are weak, with a 74.74% YoY drop in net income and an 80% YoY decline in EPS. No recent news or congress trading data to act as a catalyst.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly (-74.74% YoY) to -$10.16M, and EPS fell by 80% YoY to -0.12. Gross margin remains at 0%. The financials indicate poor performance and limited growth.
Analysts are bullish, with multiple firms raising price targets significantly (e.g., Jefferies to $42, Oppenheimer to $32, Mizuho to $30). The consensus is that soquelitinib has strong potential in atopic dermatitis and other indications. However, the current bearish price action and weak financials may limit immediate upside.
